Irbesartan/Hydrochloorthiazide Sandoz (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is indicated for hypertension, a condition characterized by elevated arterial pressure.

• Hypertension (essential): reduces systolic and diastolic blood pressure to target levels.
• Secondary hypertension: assists in controlling blood pressure when the elevation is due to an underlying disorder.
• High blood pressure: improves overall cardiovascular risk profile by maintaining recommended pressure thresholds.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction, aldosterone release and sodium retention. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit NaCl reabsorption, increasing urinary excretion of sodium and water. The combined effect reduces peripheral vascular resistance and plasma volume, leading to a synergistic decrease in systemic blood pressure.

Like all antihypertensive combinations, Irbesartan/Hydrochlorothiazide may cause adverse reactions.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance (low potassium): may cause muscle cramps or weakness.
• Fatigue: feeling of reduced energy.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Acute kidney injury: sudden decline in renal function.
• Significant hypotension: marked drop in blood pressure leading to fainting.
• Hyperkalemia: elevated potassium levels, potentially causing cardiac arrhythmias.
• Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor relevant parameters.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Renal function assessment: check serum creatinine and eGFR periodically.
• Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics.
• Hepatic impairment caution: dose adjustment may be required in severe liver disease.
• Dehydration avoidance: correct fluid deficits before starting treatment.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use may increase risk of renal impairment.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or other ARBs: additive blood‑pressure lowering effect may require dose adjustment.
• Lithium: concomitant use can raise lithium concentrations, risking toxicity.
• Antidiabetic agents: blood‑glucose control may improve, necessitating dose reevaluation.